The IJTLD is the reference for clinical research and epidemiological studies on lung health worldwide, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution.
IJTLD OPEN is our new open access journal (which is fully compliant with Plan S) and has broader scope and coverage - see here.
Both journals use single-anonymous peer review (i.e., the reviewers know the identify of the authors of an article, but the authors do not know the identity of the reviewers). This allows reviewers to give feedback without fear of any repercussions.
Our Editor-in-Chief works alongside an active Editorial Board to minimise the time taken for key peer review stages so the process is as quick as possible. Data for 2023 is:
8 Days
First Decision
3 Days
Immediate Reject
27 Days
Peer review
Please note, although authors for IJTLD and IJTLD Open submit their manuscripts via the same portal, this is to ensure we apply the same rigour to peer review for open access and subscription content. Also IJTLD Open has a much broader scope of coverage and content types compared to the more traditional IJTLD (see details here)
In preparing your article, please follow our Instructions for Authors:
Before submission, please check you have complied with our requirements using the following documents:
If you exceed our recommended article lengths additional fees may apply – see Journal Publication Charges
If you experience difficulties of any kind, please e-mail the Editorial Office.